NCT05928299

Integrative Multi-Omics Testing for Immunotherapy Response in Non-Small Cell Lung Cancer

Proteomic and Metabolomic Features Testing for Immunotherapy Response in Non-Small Cell Lung Cancer

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 400 (estimated)
• Sponsor: Nanfang Hospital, Southern Medical University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The objective of this study is to use blood and urine proteomic and metabolomic features to monitor lung cancer immunotherapy response.

Detailed description

Observational, ambispective single-center cohort study, including 400 patients with locally advanced unresectable or metastatic NSCLC who received or are receiving immunotherapy in routinely clinical practice. For the part of retrospective study，the investigators intend to include 200 patients who received immunotherapy at Nanfang Hospital from January 1, 2020 to March 1, 2023. For the part of prospective study，the investigators intend to include 200 patients who will receive immunotherapy at Nanfang Hospital from March 1, 2023 to December 31, 2025.

Conditions

• Lung Cancer

Timeline

• Start date: 2020-01-01
• Primary completion: 2025-12-31
• Completion: 2025-12-31
• First posted: 2023-07-03
• Last updated: 2023-07-03

Locations

1 site across 1 country: China